Trading Report: Today: Vertex Pharmaceuticals Inc. (VRTX) Director Sold $562,055.00 in Stock

Today: Vertex Pharmaceuticals Inc. (VRTX) Director Sold $562,055.00 in Stock

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $86.47, for a total transaction of $562,055.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at $23,755,470.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) traded down 0.99% on Monday, reaching $86.90. The company’s stock had a trading volume of 1,855,272 shares. The company has a 50-day moving average price of $83.87 and a 200 day moving average price of $89.83. The company’s market cap is $21.55 billion. Vertex Pharmaceuticals Inc. has a 12 month low of $73.31 and a 12 month high of $134.23.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by $0.02. The company had revenue of $413.78 million for the quarter, compared to analyst estimates of $423.53 million. Vertex Pharmaceuticals had a negative return on equity of 5.31% and a negative net margin of 13.45%. The firm’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.13) EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Inc. will post $0.78 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in shares of Vertex Pharmaceuticals by 1.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,483,388 shares of the pharmaceutical company’s stock valued at $2,047,986,000 after buying an additional 235,525 shares in the last quarter. Capital World Investors increased its position in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock valued at $1,944,119,000 after buying an additional 599,586 shares in the last quarter. FMR LLC increased its position in shares of Vertex Pharmaceuticals by 46.9% in the second quarter. FMR LLC now owns 22,227,104 shares of the pharmaceutical company’s stock valued at $1,911,975,000 after buying an additional 7,092,351 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Vertex Pharmaceuticals by 2.2% in the second quarter. Vanguard Group Inc. now owns 15,265,175 shares of the pharmaceutical company’s stock valued at $1,313,110,000 after buying an additional 329,337 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Vertex Pharmaceuticals by 4.2% in the second quarter. JPMorgan Chase & Co. now owns 12,173,439 shares of the pharmaceutical company’s stock valued at $1,047,161,000 after buying an additional 485,112 shares in the last quarter. Institutional investors own 95.39% of the company’s stock.

Several brokerages have commented on VRTX. Vetr upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $87.67 price target on the stock in a research report on Monday, November 21st. Janney Montgomery Scott began coverage on Vertex Pharmaceuticals in a report on Thursday, November 17th. They set a “neutral” rating and a $98.00 price objective on the stock. William Blair downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $105.00 to $81.00 in a report on Tuesday, November 1st. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, October 31st. Finally, Stifel Nicolaus restated a “buy” rating and set a $108.00 price objective (down previously from $109.00) on shares of Vertex Pharmaceuticals in a report on Friday, October 28th. Sixteen equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $108.13.

About Vertex Pharmaceuticals

Related posts

Leave a Comment